Background/aim: Invasive fungal infection (IFI) causes morbidity and mortality among patients with hematological malignancies. We evaluated the incidence and treatment characteristics of IFIs between October 2012 and December 2013. Materials and methods: Patients who received chemotherapy or stem cell transplantation were retrospectively evaluated. Fungal infections were classified according to EORTC criteria.Results: Prophylaxis and antifungal therapy were given in 30.5% and 23.6% of 522 chemotherapy courses, respectively. The incidence of proven/probable IFI was 6.7%. The incidence of IFI among patients who received prophylaxis was significantly higher than among those who did not receive it (11.3% vs. 4.6%, P = 0.005). There was no significant difference between patients who received mold-active and no mold-active prophylaxis (P = 0.098). The most common single agent therapy and causative pathogen was liposomal amphotericin B (57.1%) and Aspergillus (n = 5), respectively. IFI-attributable mortality rate was 14.2% in 6 weeks.Conclusion: The IFI incidence and mortality rate were similar to that reported in the literature. The IFI rate was higher in the group using prophylaxis, as this is a high-risk group. Although the IFI rate was not significantly different between groups using prophylaxis, patients should be followed closely for the effective use of posaconazole prophylaxis.
Invasive fungal infection, treatment, prophylaxis, hematological malignancies, epidemiology
SOYER, NUR; ÜNAL, HATİCE DEMET KİPER; VURAL, FİLİZ; ŞAHİN, FAHRİ; TÖBÜ, MAHMUT; DÖNMEZ, AYHAN; TOMBULOĞLU, MURAT; ARDA, BİLGİN; and SAYDAM, GÜRAY
"Epidemiology and analysis of invasive fungal infections in patients withhematological malignancies: a single-center real-life experience,"
Turkish Journal of Medical Sciences: Vol. 47:
5, Article 31.
Available at: https://journals.tubitak.gov.tr/medical/vol47/iss5/31